The rising incidence of autoimmune
disorders and cancers has triggered the need of effective medicine. Biologics
fit the need by targeting specific cells, while leaving other healthy cells
unharmed, to combat such diseases.
Biologics
Biologics are medicines derived from
living cells and used for treating autoimmune disorders and various types of
cancers. These medicines can target specific antigens of cancerous cells and
leave healthy cells unharmed. They are produced using recombinant DNA
technology to be used in monoclonal antibodies (mAbs), vaccines, and
therapeutic proteins. These medicines are also known as biopharmaceuticals.
Biosimilars and biobetters are
medicines have a similar composition to biologics, but are considered to be
their viable substitutes on account of their high production costs. Biobetters
even enjoy 12 years of market protection in U.S. and other regions. Major
companies are investing in the production of such medicines due to patent
expiry of blockbuster drugs like Herceptin (trastuzumab).
View summary of this report, Click Here
View summary of this report, Click Here
Latest Developments
Companies have decided to outsource
their production activities to contract manufacturing organizations (CMOs) in
order to retain their market shares. CMOs are adopting advanced expression
systems and single-use technologies to cater to increasing demand of biologics.
This would also reduce capital expenses and lower the cost of the drug.
Furthermore, the same companies are
delivering the drug in prefilled syringes and autoinjectors to ensure the
drug’s immunogenicity. These are administered subcutaneously at homes to treat
inflammation related to rheumatoid arthritis. The focus has been shifted to
better drug deliver models which are compliant to patient’s needs.
Market Overview
The worldwide biologics market is
expected to touch around USD 400 billion by 2025, according to Grand View
Research, Inc. It is expected to display a CAGR close to 4% over the forecast
period (2014 - 2025). The market is driven by increasing demand of customized
medicines by aging populace that are vulnerable to chronic diseases.
mAbs segment was the largest market
product in recent years, due to its high revenue generation. Oncology was the
biggest market application due to the launch of various biopharmaceuticals to
combat myriad version of cancer. Asia Pacific is expected to display a
significant growth rate over the forecast period. Major market players include Amgen
Inc.; AbbVie Inc.; Eli Lilly & Company; and Merck & Co. Inc.
Click Here For Access Full Report : https://goo.gl/Ju7QvC
Click Here For Access Full Report : https://goo.gl/Ju7QvC
ConversionConversion EmoticonEmoticon